Washington, D.C. - The Carnegie Institution announced today that the Carnegie board of trustees has elected Remi Barbier, founder, president & CEO of Pain Therapeutics, Inc., to their board. Pain Therapeutics is a publicly traded (NASDAQ: PTIE) biotechnology company based in South San Francisco, CA. Barbier has served as chairman of the board, president, and CEO since founding the company in 1998.

"Remi Barbier brings an impressive array of knowledge and experience from the science and business communities to our board," commented Carnegie president Richard Meserve. "He will be invaluable to the growth of the institution."

Pain Therapeutics develops novel drugs in the areas of pain management and oncology. For more information please visit the company's web site: http://www.paintrials.com/.

A life-long entrepreneur in the life sciences, Barbier has founded, co-founded or helped grow several biomedical companies, including Exelixis Inc., a leading genomics-based drug discovery company; ArQule, a chemistry company; and EnzyMed, a chemistry company now owned by Albany Molecular Research. Barbier obtained his undergraduate degree from Oberlin College and an MBA from the University of Chicago.


The Carnegie Institution of Washington (http://www.carnegieinstitution.org/), a private nonprofit organization, has been a pioneering force in basic scientific research since 1902. It has six research departments: the Geophysical Laboratory and the Department of Terrestrial Magnetism, both located in Washington, D.C.; The Observatories, in Pasadena, California, and Chile; the Department of Plant Biology and the Department of Global Ecology, in Stanford, California; and the Department of Embryology, in Baltimore, Maryland.

News Topic: